This work optimized compound combinations via a second order quadratic series, which was previously applied towards drug combination optimization against a broad spectrum of indications. In drug development, the dose selection is typically limited as toxicity and clinically actionability are critical limiting factors. However, the concentration selection of compounds in this study was not limited by induced toxicity and was mostly referenced to previous studies. The concentration levels were however limited to three per the design of OACD. Therefore, the interrogated compound-concentration parameter space was only limited to the tested concentrations. As such, downstream concentration-escalation studies or OACD designs that incorporate more concentration levels may provide further insight into concentrations that improve plant yield.